Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
Authors:
Open Access
- 9 October 2021
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (3) , 1670-1677
Abstract
Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage and progression of multiple sclerosis (MS). In European healthcare systems, however, patient access to HE DMTs in MS is often restricted to later stages of the disease due to restrictions in reimbursement despite broader regulatory labels. Although not every patient should be treated with HE DMTs at the initial stages of the disease, early and unrestricted access to HE DMTs with a positive benefit–risk profile and a reasonable value proposition will provide the freedom of choice for an appropriate treatment based on a shared decision between expert physicians and patients. This will further optimize outcomes and facilitate efficient resource allocation and sustainability in healthcare systems and society.Keywords
This publication has 34 references indexed in Scilit:
- Living with Multiple Sclerosis in Europe: Pharmacological Treatments, Cost of Illness, and Health-Related Quality of Life Across Countries2017
- Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis TreatmentsFrontiers in Neurology, 2017
- The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerationsJournal of Neurology, 2017
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisNew England Journal of Medicine, 2017
- Brain health: time matters in multiple sclerosisMultiple Sclerosis and Related Disorders, 2016
- Defining high, medium and low impact prognostic factors for developing multiple sclerosisBrain, 2015
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 2012
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- The Effect of Disease, Functional Status, and Relapses on the Utility of People with Multiple Sclerosis in the UKValue in Health, 2007
- The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and NeurodegenerationNeuron, 2006